We develop proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology and autoimmune diseases

News

11 October 2021

Biotts will develop its operations under the watchful eye of Google

invest-in-wroclaw.pl: Google has completed recruitment for a new accelerator for European startups in the field of medicine and health. At the ...

Read

22 September 2021

Biotts opens an office in Boston

ISB Zdrowie: Biotts has opened an office in Boston. Massachusetts is currently considered the place to be if you’re looking to launch a biotech ...

Read

13 September 2021

Puls Biznesu: Biotts wants to revolutionize drug delivery

Puls Biznesu: Despite years of work only 17 patch-based #transdermal_drug delivery systems were ever developed and just 10 of them – including ...

Read

15 July 2021

Diabetes and cancer will be treated through the skin. A start-up from Poland is preparing a breakthrough

WNP.PL: Biotts is picking up some serious steam after its participation in the Start-up Challenge! The Wroclaw-based startup is about to begin ...

Read
 

About BIOTTS

BIOTTS S.A. is a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology, and autoimmune diseases. The team of Biotts technologists has developed a proprietary technology for obtaining a universal transdermal therapeutic system: MTC-Y. Thanks to the unique properties of the system, it is possible to increase the bioavailability of active substances by several times, allowing active substances to penetrate through skin barriers up to several centimetres, reaching soft tissues and bones. The unique transdermal MTC-Y system can be easily modified to achieve a targeted action in pathologically changed tissues. By increasing the bioavailability of the substance, it is possible to reduce the therapeutic dose, while maintaining the original effect and, at the same time, reducing the side effects. The unique transdermal Biotts system enables the transport of one to several active substances, thanks to which it is possible to design multi-component drugs. Through simple modifications of the system, it is also possible to design medicines with a modified release profile for the medicinal substance.

How it works transdermal Biotts technology:

With more than thirty years of experience, the Research and Development Team is able to effectively create proprietary medicines, solve complex technological problems and create unique solutions to help people all over the world.

BIOTTS S.A. also provides research and development services for pharmaceutical, biotechnological, cosmetic and chemical companies from all over the world.

We have provided the market with a wide variety of solutions, including: a non-aggregating nanocarrier used in the production of vitamin preparations, anti-allergic drugs, semi-solid forms of a drug with a deep penetration carrier, semi-solid forms of a drug accelerating tissue reconstruction, cosmetic products with increased bioavailability based on natural resources, medicinal gels, stabilised and naturally preserved omega acids, and functional food formulas.

BIOTTS S.A.
Duńska 7 st.
54-427 Wrocław
office@biotts.com

Laboratories
Wrocław Technology Park
Omega Building
Duńska 7 street
54-424 Wrocław

Our clients

Investors

Partners